Regeneus Limited regeneus.com.au Full Regeneus Limited profile here

Regeneus Limited (ASX:RGS) is a regenerative medicine company that develops and commercialises proprietary technologies for the preparation of point-of-care and off-the-shelf cell therapies.

Regeneus' stem cell therapy a treatment option for neuropathic pain

Regeneus (ASX: RGS) is investigating the use of its HiQCell stem cell therapy for treating neuropathic pain, extending its use beyond treating musculoskeletal conditions, such as osteoarthritis.

This is after the publication of a paper in the Journal of Pain Research describing safety and early efficacy data for the use of HiQCell in patients suffering from persistent, severe and intolerable pain in the face and dental region.

Neuropathic pain affects up to 6% of the population.

This new study confirms that the therapy appears to offer a viable new treatment option. Regeneus Clinical Development Director Dr Richard Lilischkis said that to date the pioneering work of HiQCell has focused on the treatment of musculoskeletal conditions, such as osteoarthritis.

Following extensive research and development, we are working with our medical specialist partners to offer a therapeutic treatment option for patients suffering with neuropathic pain, he added.

We look forward to continuing offering stem cell clinical treatment options with North Shore Specialist Day Hospital to deliver high quality outcomes for patients.

Regeneus will continue to explore pain more generally and how HiQCell could be applied to other indications.

Read the original here:
Regeneus' stem cell therapy a treatment option for ...